Randall J Bateman

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker
    Randall J Bateman
    Dept of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neurology 68:666-9. 2007
  2. pmc Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects
    Saori Hata
    Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
    Mol Neurodegener 7:16. 2012
  3. pmc Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA
    Nat Med 12:856-61. 2006
  4. pmc Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
    Jacob M Basak
    Department of Neurology, Saint Louis, Missouri 63110, USA
    Mol Neurodegener 7:14. 2012
  5. pmc Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology
    Jee Hoon Roh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Sci Transl Med 4:150ra122. 2012
  6. pmc In vivo human apolipoprotein E isoform fractional turnover rates in the CNS
    Kristin R Wildsmith
    Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, United States of America
    PLoS ONE 7:e38013. 2012
  7. pmc Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
    Tammie L S Benzinger
    Departments of Radiology, Biostatistics, Neurology, Pathology and Immunology, and Psychiatry, Washington University School of Medicine, St Louis, MO, 63110
    Proc Natl Acad Sci U S A 110:E4502-9. 2013
  8. pmc Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers
    Rachel Potter
    Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Sci Transl Med 5:189ra77. 2013
  9. pmc Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics
    Kwasi G Mawuenyega
    Department of Neurology, Knight Alzheimer s Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA
    Anal Biochem 440:56-62. 2013
  10. pmc Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system
    Yafei Huang
    Department of Neurology, Washington University School of Medicine, 660 S Euclid, PO Box 8111, St Louis, MO 63110, USA
    Arch Neurol 69:51-8. 2012

Research Grants

  1. amyloid-beta metabolism/humans/Alzheimer's Disease
    Randall Bateman; Fiscal Year: 2006
  2. alphabeta AND PROTEOMIC ANALYSIS OF CSF IN AD AND AGING
    Randall Bateman; Fiscal Year: 2007
  3. A BETA METABOLISM IN ALZHEIMER DISEASE & CONTROLS
    Randall J Bateman; Fiscal Year: 2010

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker
    Randall J Bateman
    Dept of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Neurology 68:666-9. 2007
    ..To investigate the stability and time course of human CSF amyloid-beta (Abeta) levels over hours...
  2. pmc Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects
    Saori Hata
    Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
    Mol Neurodegener 7:16. 2012
    ..Aβ and p3-Alcα can be recovered from human cerebrospinal fluid (CSF). We have previously reported alternative processing of APP and Alcα in the CSF of some patients with sporadic mild cognitive impairment (MCI) and AD (SAD)...
  3. pmc Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA
    Nat Med 12:856-61. 2006
    ....
  4. pmc Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
    Jacob M Basak
    Department of Neurology, Saint Louis, Missouri 63110, USA
    Mol Neurodegener 7:14. 2012
    ..We have developed a bolus stable isotope-labeling kinetics (SILK) technique coupled with multiple reaction monitoring mass spectrometry to measure the clearance of proteins in the mouse brain...
  5. pmc Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology
    Jee Hoon Roh
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Sci Transl Med 4:150ra122. 2012
    ..Sleep-wake behavior and diurnal fluctuation of Aβ in the central nervous system may be functional and biochemical indicators, respectively, of Aβ-associated pathology...
  6. pmc In vivo human apolipoprotein E isoform fractional turnover rates in the CNS
    Kristin R Wildsmith
    Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, United States of America
    PLoS ONE 7:e38013. 2012
    ..We also demonstrate a slower turnover rate for CSF ApoE than that for amyloid beta, another molecule critically important in AD pathogenesis...
  7. pmc Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
    Tammie L S Benzinger
    Departments of Radiology, Biostatistics, Neurology, Pathology and Immunology, and Psychiatry, Washington University School of Medicine, St Louis, MO, 63110
    Proc Natl Acad Sci U S A 110:E4502-9. 2013
    ..Additional analyses of individuals in which longitudinal data were available suggested that an accelerated appearance of volumetric declines approximately coincides with the onset of the symptomatic phase of the disease. ..
  8. pmc Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers
    Rachel Potter
    Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Sci Transl Med 5:189ra77. 2013
    ....
  9. pmc Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics
    Kwasi G Mawuenyega
    Department of Neurology, Knight Alzheimer s Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110, USA
    Anal Biochem 440:56-62. 2013
    ..Because the assay does not require antibody development for each Aβ isoform peptide, significant improvements in the throughput and accuracy of isoform quantitation were achieved. ..
  10. pmc Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system
    Yafei Huang
    Department of Neurology, Washington University School of Medicine, 660 S Euclid, PO Box 8111, St Louis, MO 63110, USA
    Arch Neurol 69:51-8. 2012
    ..The amyloid hypothesis predicts that increased production or decreased clearance of β-amyloid (Aβ) leads to amyloidosis, which ultimately culminates in Alzheimer disease (AD)...
  11. pmc Decreased clearance of CNS beta-amyloid in Alzheimer's disease
    Kwasi G Mawuenyega
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 330:1774. 2010
    ..On average, there were no differences in Aβ40 or Aβ42 production rates. Thus, the common late-onset form of Alzheimer's disease is characterized by an overall impairment in Aβ clearance...
  12. pmc Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls
    Thomas J Esparza
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Ann Neurol 73:104-19. 2013
    ..However, the lack of a sensitive, specific, and quantitative assay for Aβ oligomers has hampered rigorous tests of this hypothesis...
  13. pmc Human apoE isoforms differentially regulate brain amyloid-β peptide clearance
    Joseph M Castellano
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Sci Transl Med 3:89ra57. 2011
    ..Our results suggest that APOE alleles contribute to AD risk by differentially regulating clearance of Aβ from the brain, suggesting that Aβ clearance pathways may be useful therapeutic targets for AD prevention...
  14. pmc Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry
    Kristin R Wildsmith
    Department of Neurology, Hope Center for Neurological Disorders and Alzheimer s Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Anal Biochem 395:116-8. 2009
    ..This method provides a less biased assessment of ApoE isoforms compared to antibody-dependent methods, and may lead to a better understanding of the biological differences between isoforms...
  15. pmc Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Am Soc Mass Spectrom 18:997-1006. 2007
    ..The technique is adaptable to other macromolecules, such as carbohydrates or lipids...
  16. pmc A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Ann Neurol 66:48-54. 2009
    ..The objective of this study was to determine the effects of a gamma-secretase inhibitor on the production of Abeta in the human CNS...
  17. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
    ..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
  18. pmc Clinical and biomarker changes in dominantly inherited Alzheimer's disease
    Randall J Bateman
    Washington University School of Medicine, Department of Neurology, 660 S Euclid Ave, Box 8111, St Louis, MO 63110, USA
    N Engl J Med 367:795-804. 2012
    ..Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease...
  19. pmc Exposure of the lysine in the gamma chain dodecapeptide of human fibrinogen is not enhanced by adsorption to poly(ethylene terephthalate) as measured by biotinylation and mass spectrometry
    Vitaliy Ovod
    Department of Biomedical Engineering and Center for Materials Innovation, Washington University, St Louis, Missouri, USA
    J Biomed Mater Res A 100:622-31. 2012
    ..The results do not directly address but are consistent with the hypothesis that only activated platelets adhere to adsorbed fibrinogen...
  20. pmc Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle
    Jae Eun Kang
    Department of Neurology, Washington University, St Louis, MO 63110, USA
    Science 326:1005-7. 2009
    ..Thus, the sleep-wake cycle and orexin may play a role in the pathogenesis of Alzheimer's disease...
  21. pmc Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Neurotherapeutics 5:381-90. 2008
    ..This review covers the current methods and technologies used in the therapeutic translation of proposed disease-modifying therapies for AD...
  22. pmc Stable isotope labeling tandem mass spectrometry (SILT): integration with peptide identification and extension to data-dependent scans
    Donald L Elbert
    Department of Biomedical Engineering and Center for Materials Innovation, Washington University, St Louis, Missouri, USA
    J Proteome Res 7:4546-56. 2008
    ..The combination of identification with SILT facilitates quantitation without peak detection and helps to ensure the appropriate use of variable modifications for kinetics experiments...
  23. ncbi request reprint Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ
    Ping Yan
    Department of Neurology and the Hope Center for Neurological Disorders, Division of Endocrinology, Diabetes, Metabolism, and Lipid Research, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 281:24566-74. 2006
    ..These findings suggest that MMP-9 can degrade fAbeta and may contribute to ongoing clearance of plaques from amyloid-laden brains...
  24. ncbi request reprint Testing a test for Alzheimer disease
    Randall J Bateman
    Neurology 68:482-3. 2007

Research Grants6

  1. amyloid-beta metabolism/humans/Alzheimer's Disease
    Randall Bateman; Fiscal Year: 2006
    ..younger age, and 3) ApoE4 positive vs. ApoE4 negative. A detectable change in Abeta metabolism in humans that is associated with AD may ultimately lead to better diagnostic and therapeutic options. ..
  2. alphabeta AND PROTEOMIC ANALYSIS OF CSF IN AD AND AGING
    Randall Bateman; Fiscal Year: 2007
    ..younger age, and 3) ApoE4 positive vs. ApoE4 negative. A detectable change in A¿ metabolism in humans that is associated with AD may ultimately lead to better diagnostic and therapeutic options. ..
  3. A BETA METABOLISM IN ALZHEIMER DISEASE & CONTROLS
    Randall J Bateman; Fiscal Year: 2010
    ..Eventually, this may lead to improved diagnostic or predictive testing for AD as well as aid in the evaluation of new disease modifying therapeutics. ..